论文部分内容阅读
目的探讨伏格列波糖对糖尿病患者肝脏毒性的影响。方法 2型糖尿病患者56例,分为肝功能正常组(32例)和肝功能轻度异常组(24例),均给予两组患者服用12周的伏格列波糖进行治疗,观察比较两组患者的肝功能指标和血糖变化情况。结果经过治疗后肝功能正常组和肝功能轻度异常组患者的血糖均下降,但两组患者在治疗前后的肝功能指标(丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、直接胆红素(DBIL)、总胆汁酸(TA))的变化不明显,差异无统计学意义(P>0.05)。结论伏格列波糖可以改善糖尿病患者的高血糖症状,在治疗过程中并未产生肝脏毒性。
Objective To investigate the effect of voglibose on hepatic toxicity in diabetic patients. Methods Fifty-six patients with type 2 diabetes mellitus were divided into two groups: normal liver function group (32 cases) and mild dysfunction group (24 cases). Both groups were treated with voglibose for 12 weeks. Group of patients with liver function indicators and blood glucose changes. Results After treatment, the blood glucose of patients with normal liver function group and mild abnormal liver function group decreased. However, the liver function indexes (ALT, AST, TBIL, DBIL, TA) had no significant difference (P> 0.05). Conclusion Voglibose can improve the symptoms of hyperglycemia in diabetic patients and did not produce liver toxicity during the treatment.